Immix Biopharma's NXC-201 Phase 2 Trial Shows 75% Complete Response Rate
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 11 hour ago0mins
- Clinical Trial Results: NXC-201 achieved a 75% complete response (CR) rate in 20 patients, demonstrating the therapy's potential to address significant unmet medical needs in relapsed/refractory AL Amyloidosis.
- Future Expectations: Among five pending patients, minimal residual disease (MRD) negativity in bone marrow predicts a potential increase in future CR rates to 95%, which could enhance the clinical applicability of NXC-201.
- Market Opportunity: The number of AL Amyloidosis patients is projected to reach approximately 38,500 by 2026, growing at a rate of 12% per year, providing a substantial market for NXC-201.
- Regulatory Progress: The final readout and Biologics License Application (BLA) submission for NEXICART-2 are planned for 2026, marking a significant milestone for ImmixBio in advancing NXC-201 towards commercialization.
IMMX.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on IMMX
Wall Street analysts forecast IMMX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.840
Low
8.00
Averages
8.00
High
8.00
Current: 4.840
Low
8.00
Averages
8.00
High
8.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$7 -> $8
2025-09-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $8
2025-09-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Immix Biopharma to $8 from $7 and keeps a Buy rating on the shares after the company received a strategic investment from Goose Capital and former Tanox CEO Dr. Nancy Chang. The capital provides for an operational runway into Q2 of 2026 for Immix, the analyst tells investors in a research note.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$7
2025-02-10
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$7
2025-02-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$7
2025-01-06
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$7
2025-01-06
Reiterates
Strong Buy
Reason
See All Ratings
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?